Pub-2020

Articles

Title
Zanubrutinib for the treatment of MYD88 wild-type WM: a substudy of the phase 3 ASPEN trial
The race to stymie BTK: zanu zings
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Response and Survival Outcomes to Ibrutinib monotherapy for patients with WM on & off Clinical Trials
A prognostic index predicting survival in transformed WM
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WM: the ASPEN study
Partial response or better at six months is prognostic of superior progression-free survival in WM patients treated with Ibrutinib
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated WM
Management of Waldenstrom's Macroglobulinemia in 2020
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WM
Long-Term Follow-up of Ibrutinib Monotherapy in Symptomatic, Previously Treated patient with WM
Ixazomib, Dexamethasone, and Rituximab in treatment-naive patients with WM: Long-term follow-up
Genomic Landscape of WM and its Impact on Treatment Strategies
Genomic evolution of ibrutinib-resistant clones in WM
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
Epigenomics in Waldenstrom Macroglobulinemia
Discovery of a Selective Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma
CXCR4 mutational status does not impact outcomes in patients w WM treated with proteosome inhibitors
CXCR4 in WM: chances and challenges
Consensus Treatment recommmendations from the 10th International Workshop for WM
Consensus Statement on the Management of WM Patients During COVID19 Pandemic
Comparative genomics of CXCR4MUT and CXCR4WT single cells in WM
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID19 infected patients
A prognostic index predicting survival in transformed WM